Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 8:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 7,077 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasms Clear all
Completed Phase 2 Interventional Results available

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

NCT01849250
View directory record Official record
Conditions
Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ, Paget Disease of the Breast, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Docosahexaenoic Acid, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Oct 28, 2026, 8:43 PM EDT
Terminated Phase 2 Interventional Results available

Lonafarnib in Metastatic Breast Cancer

NCT00773474
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Lonafarnib
Drug
Lead sponsor
George Sledge
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Galesburg, Illinois • Bloomington, Indiana • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Oct 28, 2026, 8:43 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03170960
View directory record Official record
Conditions
Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer
Interventions
cabozantinib, atezolizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
57
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing Breast, Cervical, and Colorectal Cancer Screening and HPV Vaccination Among Underserved Texans

NCT04638010
View directory record Official record
Conditions
Cancer Prevention
Interventions
Cancer control navigation (CNN), General referral (usual care)
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
1,554 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Not applicable Interventional

Intellectual Impairment in Women With Breast Cancer

NCT00896324
View directory record Official record
Conditions
Breast Cancer
Interventions
Cognitive Rehabilitation, Active Neurofeedback Training, Neurofeedback Training (placebo / Sham)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Not applicable Interventional Results available

Online Dietary and Resistance Training to Improve Physical Function in Older Cancer Survivors, E-PROOF Trial

NCT06016725
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage I Prostate Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions
Exercise Intervention, Informational Intervention, Nutritional Assessment, Physical Performance Testing, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 28, 2026, 8:43 PM EDT
Not yet recruiting Not applicable Interventional

Adjuvant Endocrine Therapy Adherence Intervention Pilot in Rwanda

NCT07562399
View directory record Official record
Conditions
Medication Adherence, Breast Cancer
Interventions
Educational video, Symptom monitoring card, Text reminders
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 28, 2026, 8:43 PM EDT
Completed No phase listed Observational

Breast Cancers: Risk Factors Among Mexican Women in Mexico, Mexican-American and African-American Women in the U.S.

NCT00837499
View directory record Official record
Conditions
Breast Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
938 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
4
States / cities
Tucson, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 28, 2026, 8:43 PM EDT
Recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06790693
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Placebo, CDK4/6i, Letrozole
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
62
States / cities
Goodyear, Arizona • Phoenix, Arizona • Burbank, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 8:43 PM EDT
Active, not recruiting Not applicable Interventional

The Preoperative Health & Body Study

NCT01516190
View directory record Official record
Conditions
Breast Cancer
Interventions
Exercise, Surgical preparation program
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 28, 2026, 8:43 PM EDT
Terminated No phase listed Observational

A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide

NCT05414123
View directory record Official record
Conditions
Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Breast Cancer, Non-Small Cell Lung Cancer
Interventions
CNSide
Device
Lead sponsor
Biocept, Inc.
Industry
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Stanford, California • Chicago, Illinois • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 28, 2026, 8:43 PM EDT
Active, not recruiting Phase 1 Interventional

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer

NCT03083288
View directory record Official record
Conditions
Breast Cancer
Interventions
[18F]FluorThanatrace
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers

NCT05438303
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD9833, Midazolam, Omeprazole, Dabigatran Etexilate, Celecoxib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 70 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Long Beach, California • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Not applicable Interventional Results available

Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Breast Cancer

NCT03650803
View directory record Official record
Conditions
Breast Cancer
Interventions
3D MR Fingerprinting scan
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Two Dimensional (2D) Silicon Transducer-Compression Plates for Breast Ultrasound

NCT00859261
View directory record Official record
Conditions
Breast Tumor, Breast Cysts
Interventions
Experimental 3D Breast Ultrasound imaging, Experimental Photoacoustic Imaging
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 80 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Oct 28, 2026, 8:43 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery

NCT05457842
View directory record Official record
Conditions
Sentinel Lymph Node Biopsy, Breast Cancer, Melanoma
Interventions
pudexacianinium chloride
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 28, 2026, 8:43 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

NCT04354064
View directory record Official record
Conditions
Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 28, 2026, 8:43 PM EDT
Terminated Phase 1 Interventional

Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer

NCT00039455
View directory record Official record
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
trastuzumab, alvocidib, laboratory biomarker analysis, pharmacological study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

NCT03719326
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Ovarian Cancer
Interventions
Etrumadenant, IPI-549, Pegylated liposomal doxorubicin (PLD), nanoparticle albumin-bound paclitaxel (NP)
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
20
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Phase 2 Interventional

EPO906 Therapy in Patients With Advanced Breast Cancer

NCT00035126
View directory record Official record
Conditions
Breast Neoplasms
Interventions
epothilone b
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
2
States / cities
Lebanon, New Hampshire • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Not applicable Interventional

Health Education Intervention in Reducing Weight Gain in Patients With Newly Diagnosed Stage I-IV Breast Cancer Undergoing Chemotherapy

NCT01941784
View directory record Official record
Conditions
Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
educational intervention, counseling intervention, telephone-based intervention, questionnaire administration, quality-of-life assessment
Other · Behavioral · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Phase 2 Interventional Results available

A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

NCT01196052
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Fort Myers, Florida • Lafayette, Indiana • Scarborough, Maine + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Oct 28, 2026, 8:43 PM EDT
Terminated Phase 1 Interventional

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

NCT06052852
View directory record Official record
Conditions
Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Melanoma
Interventions
BDC-3042, Cemiplimab
Drug
Lead sponsor
Bolt Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Palo Alto, California • Boston, Massachusetts • Austin, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Not applicable Interventional

Trial of a Mammography Decision Aid for Women Aged 75 and Older

NCT02198690
View directory record Official record
Conditions
Breast Cancer Screening
Interventions
Mammography decision aid, Home safety pamphlet
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
75 Years to 89 Years · Female only
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 28, 2026, 8:43 PM EDT